



Press release

SHL appoints Yossi Vadnagra as CFO

Tel Aviv / Zurich, 15 June 2017 – SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN, OTCPK: SMDCY) (“SHL”), a leading provider and developer of advanced personal telemedicine solutions, announced today that Yossi Vadnagra, its interim acting CFO since April this year, will become the company’s new CFO, effective immediately.

Yoav Rubinstein, CEO SHL Telemedicine, commented: “Yossi Vadnagra has an extensive financial, operational and business development background and specific experience in healthcare services both locally as well as internationally. I welcome Yossi to the management team of SHL and I am confident in his ability to make a significant contribution to our business.”

Yossi Vadnagra joined SHL in 2017 as Director Business Development Israel. In April 2017, he was appointed interim acting CFO of SHL. Before joining SHL, he worked for six years as Chief Financial Officer and Co-CEO for G&V Business Solutions Ltd. in Israel and India, and in this capacity, worked with SHL on business development projects in India. Prior to that, Yossi worked for five years as Chief Financial Officer and Strategic Planning for Elbit India Healthcare, a subsidiary of Elbit Imaging Ltd. (NASDAQ: EMITF). Yossi Vadnagra holds an MBA with honors from the College of Management, Israel and is a Certified Public Accountant (CPA). Nationality: Israeli.

For further information, please contact:

Martin Meier-Pfister, IRF Communications, phone: +41 43 244 81 40, shl@irfcom.ch

About SHL Telemedicine

SHL Telemedicine is engaged in developing and marketing personal telemedicine systems and the provision of medical call center services, with a focus on cardiovascular and related diseases, to end users and to the healthcare community. SHL Telemedicine offers its services and personal telemedicine devices to subscribers utilizing telephonic and Internet communication technology. SHL is listed on the SIX Swiss Exchange (SHLTN, ISIN: IL0010855885, Security No.: 1128957) and has an ADR program listed over-the counter; Symbol: SMDCY. For more information, please visit the web site at www.shl-telemedicine.com.

Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. SHL Telemedicine undertakes no obligation to publicly update or revise any forward-looking statements.